Handelsavisen
prelaunch
Companies ›Healthcare ›131030.KQ
13
131030.KQ — KOSDAQ Pharmaceuticals

131030.Kq

$8 210,00
Open in Charts → Attach watcher ⌖
— —
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
137,9B KRW
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
10,2 %
ROE
6,9 %
Net margin
13,0 %
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

131030.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and medical products.

Business. 131030.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and medical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
6,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 131030.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 131030.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    131030.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and medical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 2.62 and cash and equivalents amounting to 9,999,999,850 KRW. Its debt-to-equity ratio is very low at 0.01, indicating minimal leverage and a conservative capital structure. Despite this, the company reported a negative free cash flow of -28,975,131,120 KRW, largely driven by a significant capital expenditure of -45,041,307,480 KRW.

    In terms of profitability, the company's return on equity (ROE) is 6.88%, and its return on assets (ROA) is 5.94%, both of which are in line with industry norms. The company's operating margin is 10.18% (calculated as operating income of 8,875,109,030 KRW divided by revenue of 87,161,378,630 KRW), which is a strong indicator of operational efficiency.

    The company's revenue is not segmented by geographic region or product line in the available data, but its total revenue of 87,161,378,630 KRW suggests a broad market presence. There is no indication of significant revenue concentration in a single region or product category.

    Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's price-to-earnings ratio of 10.22 and price-to-book ratio of 0.7 suggest that it is currently undervalued relative to its earnings and book value.

    The company's risk profile is low, with no immediate liquidity or dilution concerns identified. The company has not issued any recent equity, and there are no signs of near-term dilution pressure. The company's conservative capital structure and strong liquidity position further support its low-risk profile.

    There are no recent filings or transcripts that indicate significant changes in the company's operations or strategy. The company's financial performance remains stable, with no major disruptions reported in the latest available data.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 2.62 and a low debt-to-equity ratio of 0.01.
    • The company's ROE of 6.88% and ROA of 5.94% indicate solid profitability and efficient use of assets.
    • The company's price-to-earnings ratio of 10.22 and price-to-book ratio of 0.7 suggest it is undervalued.
    • The company's free cash flow is negative due to high capital expenditures, but its liquidity position remains strong.
    • The company's risk profile is low, with no immediate liquidity or dilution concerns.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $8 210,00
    Market cap
    $116.06B
    Enterprise valueⓘ
    $107.04B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    6.6x
    P / Bⓘ
    0.7x
    P / Tangible bookⓘ
    0.7x
    Tangible book
    $165.01B
    Net cashⓘ
    $9.03B
    Current ratioⓘ
    2.6
    Debt / equityⓘ
    0.0
    ROAⓘ
    5.9%
    ROEⓘ
    6.9%
    Cash conversionⓘ
    143.0%
    CapEx / revenueⓘ
    -51.7%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin10,2 %Above median
    Net Margin13,0 %Above P75
    ROE6,9 %Above median
    Capex / Rev-51,7 %Bottom quartile
    D/E0,01Above median
    Cash Conv1,43Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 131030.KQ Market data — financials · 2026-05-26
    • Optus Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    131030.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage